What type of study is this?

This is a Cohort Study study (also classified as: Animal Study, Human Clinical Trial).

October 23, 2025Blood AdvancesOpen Access

Pyruvate kinase M2 promotes venous thrombosis by enhancing SNAP23-mediated platelet exocytosis and consequent NETosis

View Full Paper

Ask AI

Bookmark

Authors

Genetic or pharmacological targeting of PKM2 reduces thrombus formation in deep vein thrombosis, highlighting potential therapeutic avenues.

Reduced venous thrombosis observed in models targeting pyruvate kinase M2's function, indicating a new pathobiology insight.
After 48 hours in the inferior vena cava stenosis model, thrombus burden was significantly lower when targeting PKM2.
Analysis utilized both murine models and human whole blood perfusion methods to gather relevant data.
Findings suggest potential implications for developing treatments that address NETosis and thrombus formation.

Nayak et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

October 23, 2025Blood AdvancesOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Genetic or pharmacological targeting of PKM2 reduces thrombus formation in deep vein thrombosis, highlighting potential therapeutic avenues.

Reduced venous thrombosis observed in models targeting pyruvate kinase M2's function, indicating a new pathobiology insight.
After 48 hours in the inferior vena cava stenosis model, thrombus burden was significantly lower when targeting PKM2.
Analysis utilized both murine models and human whole blood perfusion methods to gather relevant data.
Findings suggest potential implications for developing treatments that address NETosis and thrombus formation.

Nayak et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark